Trials / Unknown
UnknownNCT02513342
Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma
Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients：a Randomized Controlled,Open, Multicenter Clinical Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Nanjing NingQi Medicine Science and Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection pump combined DP scheme for first-line advanced lung squamous carcinoma and maintenance treatment., and explore the predicted biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Endostar | Endostar 30mg continuous intravenous injection pump,d1-d7； |
| DRUG | Docetaxel | d4 Docetaxel，75（mg/m2），iv； |
| DRUG | Cisplatin | d4，cisplatin，75（mg/m2），iv； |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2017-10-01
- Completion
- 2018-04-01
- First posted
- 2015-07-31
- Last updated
- 2015-07-31
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02513342. Inclusion in this directory is not an endorsement.